DISCOVER is a large PrEP clinical trial, with over 5300 participants2,3
Data from a randomized, active-controlled, double-blind study of adult HIV-seronegative MSM and TGW (N=5387) using once-daily DESCOVY FOR PrEP® (n=2694) vs FTC/TDF (n=2693).1,2
DESCOVY FOR PrEP was noninferior to FTC/TDF through 96 weeks1,2
HIV incidence rate (DESCOVY vs FTC/TDF)
Primary endpoint analysis*: 0.16/100 PY vs 0.34/100 PY (IRR=0.47; CI: 0.19-1.15)
Baseline through 96-week analysis†: 0.16/100 PY vs 0.30/100 PY (IRR=0.54; CI: 0.23-1.26)
Study outcomes were similar across subgroups of age, race, gender identity, and baseline FTC/TDF use.
Nearly all patients remained HIV negative over 144 weeks1,2,4
Analysis from baseline to over 144 weeks
- HIV incidence rate: 0.13/100 PY
*When 100% of participants reached Week 48 and ≥50% reached Week 96.
†When 100% of participants reached Week 96.
*When 100% of participants reached Week 48 and ≥50% reached Week 96.
†When 100% of participants reached Week 96.
DESCOVY FOR PrEP was studied over 144 weeks in the DISCOVER Trial1,2,4
At entry and Q12W, participants were offered:
- Adherence counseling
- Prevention services (risk-reduction counseling, condoms)
Primary endpoint analysis (n=5335):
HIV incidence/100 PY when 100% of participants reached Week 48 and ≥50% reached Week 96. Secondary analysis was conducted when 100% of participants reached Week 96.
Analysis from baseline through 96 weeks (DESCOVY vs FTC/TDF):
-
Includes participants from both study arms in the 1:1 randomized, active-controlled, double-blind phase,
from baseline through 96 weeks
- Participants received either DESCOVY or FTC/TDF once daily
Analysis from baseline to ≥144 weeks (DESCOVY):
-
Includes participants who initiated DESCOVY at baseline, through 96 weeks in the double-blind phase, and
voluntarily continued on DESCOVY during the unblinded, open-label extension phase for another 48 weeks
or more
- Participants received DESCOVY once daily
Participants selected for inclusion had significant risk of acquiring HIV2,5
| Baseline demographics |
DESCOVY (n=2694) |
FTC/TDF (n=2693) |
|---|---|---|
| Median age, years (IQR) |
34 (28-43) |
34 (28-44) |
| Sex/gender | ||
| Cis male | 2649 | 2664 |
| TGW | 45 | 29 |
| Race | ||
| White | 2264 | 2247 |
| Blacka | 240 | 234 |
| Asian | 113 | 120 |
| Ethnicity | ||
| Hispanic or Latine | 635 | 683 |
| Baseline demographics |
DESCOVY (n=2694) | FTC/TDF (n=2693) |
|---|---|---|
| Baseline HIV risk factors | ||
| ≥2 condomless anal sex partners, past 12 weeks |
62% | 60% |
| Rectal gonorrhea, past 24 weeks |
10% | 10% |
| Rectal chlamydia, past 24 weeks |
13% | 12% |
| Syphilis, past 24 weeks |
9% | 10% |
| Recreational drug use, past 12 weeks |
67% | 67% |
| Binge drinkingb | 23% | 22% |
| Taking FTC/TDF at baseline | 17% | 16% |
Consider proven HIV prevention data from a large PrEP clinical trial.
You may also be interested in:
aIncludes mixed Black race.
b≥6 drinks ≥1 occasion, at least monthly.
CI=confidence interval; FTC/TDF=emtricitabine/tenofovir disoproxil fumarate; IQR=interquartile range; IRR=incidence rate ratio; Latine=a person of Latin American heritage; MSM=men who have sex with men; PrEP=pre-exposure prophylaxis; PY=person-years; Q12W=every 12 weeks; TGW=transgender women (who have sex with men).
Review the safety profile for DESCOVY, including side effects (adverse events).
Discover the impact of DESCOVY on markers of renal function.
Learn more about the co-pay program to help eligible patients receive DESCOVY.
Find answers to frequently asked questions (FAQs).
Learn more about once-daily dosing with DESCOVY.
See how to initiate DESCOVY.